{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:02:15Z","timestamp":1791028935836,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.bbapap.2006.08.001","type":"journal-article","created":{"date-parts":[[2006,8,6]],"date-time":"2006-08-06T11:03:05Z","timestamp":1154862185000},"page":"1436-1446","source":"Crossref","is-referenced-by-count":36,"title":["Protection against glycation and similar post-translational modifications of proteins"],"prefix":"10.1016","volume":"1764","author":[{"given":"John J.","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ganea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbapap.2006.08.001_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-3233(08)60066-2","article-title":"Nonenzymatic post-translational modification of proteins in vivo","volume":"37","author":"Harding","year":"1985","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1126\/science.12192669","article-title":"Reaction of monosaccharides with proteins: possible evolutionary significance","volume":"213","author":"Bunn","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.bbapap.2006.08.001_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.33549\/physiolres.930430","article-title":"Advanced glycation end-products and the progress of diabetic vascular complications","volume":"53","author":"Jakus","year":"2004","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00726-003-0017-9","article-title":"Maillard reaction products in tissue proteins: new products and new perspectives","volume":"25","author":"Thorpe","year":"2003","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbapap.2006.08.001_bib5","unstructured":"Harding, J.J., in press. Protein glycation and cataract: a conformational disease. In: Protein misfolding, aggregation and conformational disease\u2019 vol. II., Eds. Uversky, V.N. and Fink, A.L."},{"key":"10.1016\/j.bbapap.2006.08.001_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1681\/ASN.V72183","article-title":"Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy","volume":"7","author":"Cohen","year":"1996","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1042\/bst0311413","volume":"31","author":"Januszewski","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbapap.2006.08.001_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/bj2460761","article-title":"Conformational changes induced in lens \u03b1- and \u03b3-crystallins by modification by glucose 6-phosphate. Implications for cataract","volume":"246","author":"Beswick","year":"1987","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2006.08.001_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-4835(91)90260-L","article-title":"Non-enzymic modification of lens proteins by glucose and fructose: effects of ibuprofen","volume":"52","author":"Raza","year":"1991","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib10","doi-asserted-by":"crossref","first-page":"24907","DOI":"10.1074\/jbc.M202681200","article-title":"Identification and quantification of major Maillard cross-links in human serum albumin and lens protein","volume":"277","author":"Biemel","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib11","series-title":"Cellular Dysfunction in Atherosclerosis and Diabetes","first-page":"205","article-title":"Prevention of insulin glycation by metabolic and synthetic inhibitors","author":"Ganea","year":"2004"},{"key":"10.1016\/j.bbapap.2006.08.001_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM198602133140702","article-title":"Relation between complications of type I diabetes mellitus and collagen-linked fluorescence","volume":"314","author":"Monnier","year":"1986","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.bbapap.2006.08.001_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00573477","article-title":"Advanced Maillard reaction products as markers for tissue damage in diabetes and uraemia: relevance to diabetic nephropathy","volume":"29","author":"Monnier","year":"1992","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0074-7742(02)50072-6","article-title":"Glycation in diabetic neuropathy: characteristics, consequences, causes and therapeutic options","volume":"50","author":"Thornalley","year":"2002","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib15","series-title":"Cellular dysfunction in atherosclerosis and diabetes","first-page":"73","article-title":"Endothelial cell\u2014A key player in all stages of atherosclerosis","author":"Simionescu","year":"2005"},{"key":"10.1016\/j.bbapap.2006.08.001_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cercor\/bhh123","article-title":"Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains","volume":"15","author":"Luth","year":"2005","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.bbapap.2006.08.001_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/aje\/kwh161","article-title":"Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults","volume":"159","author":"Coughlin","year":"2004","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2003.08.014","article-title":"Intervention against the Maillard reaction in vivo","volume":"419","author":"Monnier","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1056-8727(03)00009-6","article-title":"Pharmacological prevention of diabetic cataract","volume":"18","author":"Kyselova","year":"2004","journal-title":"J. Diab. Comp."},{"key":"10.1016\/j.bbapap.2006.08.001_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2337\/diabetes.48.4.870","article-title":"Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes","volume":"48","author":"Mnnier","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbapap.2006.08.001_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-4835(88)90023-1","article-title":"Non-enzymic glycosylation (glycation) of lens proteins and protection by aspirin and reduced glutathione","volume":"47","author":"Huby","year":"1988","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib23","first-page":"1120","article-title":"Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo","volume":"30","author":"Swamy","year":"1989","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-4835(89)90073-0","article-title":"The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione","volume":"49","author":"Ajiboye","year":"1989","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0014-4835(85)90014-4","article-title":"Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract","volume":"40","author":"Crompton","year":"1985","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib26","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/0006-291X(85)91057-5","article-title":"Acetylation of lens crystallins: a possible mechanism by which aspirin could prevent cataract formation","volume":"128","author":"Rao","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2006.08.001_bib27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0006-291X(88)80463-7","article-title":"Aspirin prevents the nonenzymic glycosylation and carbamylation of the human eye lens crystallins in vitro","volume":"151","author":"Rao","year":"1988","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2006.08.001_bib28","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/pro.5560070622","article-title":"In vivo acetylation identified at lysine 70 of human lens \u03b1A-crystallin","volume":"7","author":"Lin","year":"1998","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-4835(90)90226-K","article-title":"Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose","volume":"50","author":"Roberts","year":"1990","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0167-4838(92)90270-N","article-title":"Glycation of human serum: inhibition by diclofenac","volume":"1120","author":"Van Boekel","year":"1992","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0925-4439(95)00120-4","article-title":"Glycation-induced inactivation of malate dehydrogenase protection by aspirin and a lens molecular chaperone, alpha-crystallin","volume":"13115","author":"Heath","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0306-3623(98)00016-0","article-title":"Reducing sugars trigger \u03b4-aminolevulinic dehydratase inactivation: evidence of in vitro aspirin prevention","volume":"31","author":"Caballero","year":"1998","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0925-4439(02)00049-2","article-title":"Protective effects of ibuprofen and its major metabolites against in vitro inactivation of catalase and fumarase: relevance to cataract","volume":"1587","author":"Shyadehi","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0014-4835(92)90129-G","article-title":"Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen","volume":"54","author":"Blakytny","year":"1992","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib35","first-page":"607","article-title":"Aspirin and senile cataracts in rheumatoid arthritis","author":"Cotlier","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.bbapap.2006.08.001_bib36","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(86)91834-9","article-title":"Do aspirin-like analgesics protect against cataract?","author":"Van Heyningen","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.bbapap.2006.08.001_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.72.11.809","article-title":"Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide","volume":"72","author":"Harding","year":"1988","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1755-3768.1989.tb04102.x","article-title":"Protection against cataract by aspirin, paracetamol and ibuprofen","volume":"67","author":"Harding","year":"1989","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.1989.01070010688028","article-title":"India\u2013US case-control study of age-related cataracts","volume":"107","author":"Mohan","year":"1989","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1076\/opep.5.3.133.8368","article-title":"Low-dose aspirin and risk of cataract and subtypes in a randomised trial of US physicians","volume":"5","author":"Christen","year":"1998","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.abb.2003.08.012","article-title":"Intervention strategies to prevent pathogenetic effects of glycated albumin","volume":"419","author":"Cohen","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00002512-200118070-00001","article-title":"Can drugs or micronutrients prevent cataract?","volume":"18","author":"Harding","year":"2001","journal-title":"Drugs Ageing"},{"key":"10.1016\/j.bbapap.2006.08.001_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1006\/exer.1998.0547","article-title":"Beneficial effect of lysine and amino acids on cataractogenesis in experimental diabetes through possible anti-glycation of lens proteins","volume":"67","author":"Sulochana","year":"1998","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2004.09.004","article-title":"Inhibition of in vitro pyrraline formation by l-arginine and polyamines","volume":"58","author":"Mendez","year":"2004","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.bbapap.2006.08.001_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0014-5793(95)00849-5","article-title":"Non-enzymatic glycosylation of the dipeptide l-carnosine, a potential anti-protein-cross-linking agent","volume":"371","author":"Hipkiss","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbapap.2006.08.001_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/psc.451","article-title":"Inhibition of ascorbic acid-induced modifications in lens proteins by peptides","volume":"9","author":"Argirova","year":"2003","journal-title":"J. Pep. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002040050623","article-title":"Carnosine prevents glyceraldehyde 3-phosphate-mediated inhibition of aspartate aminotransferase","volume":"73","author":"Swearengin","year":"1999","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1271\/bbb.66.36","article-title":"Effect of carnosine and related compounds on the inactivation of human Cu,Zn-superoxide dismutase by modification with fructose and glycolaldehyde","volume":"66","author":"Ukeda","year":"2002","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib49","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bbadis.2004.11.008","article-title":"Carnosine protects against the inactivation of esterase induced by glycation and a steroid","volume":"1741","author":"Yan","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib50","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0891-5849(00)00270-7","article-title":"Carnosine reacts with a glycated protein","volume":"28","author":"Brownson","year":"2000","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.bbapap.2006.08.001_bib51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.abb.2004.04.024","article-title":"Carnosine disaggregates glycated \u03b1-crystallin: an in vitro study","volume":"427","author":"Seidler","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib52","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0196-9781(01)00407-7","article-title":"N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts","volume":"22","author":"Babizhayev","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.bbapap.2006.08.001_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbagen.2005.04.003","article-title":"Glucose-derived Amadori compounds of glutathione","volume":"1724","author":"Linetsky","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-4165(02)00525-1","article-title":"Covalent coupling of reduced glutathione with ribose: loss of cosubstrate ability to glutathione reductase","volume":"1620","author":"Januel","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib55","series-title":"Post-translational modification of proteins","first-page":"53","article-title":"Advanced glycation endproducts","author":"Bucala","year":"1991"},{"key":"10.1016\/j.bbapap.2006.08.001_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ddr.430320204","article-title":"Advanced glycation endproducts: role in diabetic and non-diabetic vascular disease","volume":"32","author":"Bucala","year":"1994","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib57","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0024-3205(88)90484-5","article-title":"Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymic glycosylation","volume":"43","author":"Khatami","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0014-4835(90)90033-Q","article-title":"The effects of aminoguanidine on glycation (non-enzymic glycosylation) of lens proteins","volume":"50","author":"Lewis","year":"1990","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.abb.2003.08.013","article-title":"Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts","volume":"419","author":"Thornalley","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0006-2952(00)00287-2","article-title":"Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions","volume":"60","author":"Thornalley","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.abb.2003.08.017","article-title":"Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease","volume":"419","author":"Jerums","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1006\/exer.1996.0061","article-title":"Inhibition of cataracts in moderately diabetic rats by aminoguanidine","volume":"62","author":"Swamy-Mruthinti","year":"1996","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2004.09.006","article-title":"Reversal by aminoguanidine of the age-related increase in glycoxidation and lipoxidation in the cardiovascular system of Fischer 344 rats","volume":"69","author":"Moreau","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0009-8981(00)00327-2","article-title":"Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation","volume":"301","author":"Rahbar","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.abb.2003.08.009","article-title":"Novel inhibitors of advanced glycation endproducts","volume":"419","author":"Rahbar","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cccn.2005.02.012","article-title":"Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal","volume":"358","author":"Kiho","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/diabetes.48.1.198","article-title":"Metformin reduces systemic methylglyoxal levels in type 2 diabetes","volume":"48","author":"Beisswenger","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib68","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0006-2952(99)00263-4","article-title":"Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation","volume":"58","author":"Ruggiero-Lopez","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0006-2952(01)00915-7","article-title":"Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress","volume":"63","author":"Wondrak","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/bbrc.1996.0366","article-title":"Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation endproducts: comparison with aminoguanidine","volume":"220","author":"Booth","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2006.08.001_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.abb.2003.08.021","article-title":"Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications","volume":"419","author":"Metz","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib72","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0014-2999(99)00471-9","article-title":"Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal","volume":"378","author":"Taguchi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0003-9861(02)00067-X","article-title":"Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal","volume":"402","author":"Nagaraj","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib74","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.2337\/diabetes.51.9.2826","article-title":"The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes","volume":"51","author":"Stitt","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib75","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1681\/ASN.V1191719","article-title":"Mechanism of the inhibitory effect of OPB-9195 [(+\/\u2212)-2-isopropylidinehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation","volume":"11","author":"Miyata","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2362.2001.00826.x","article-title":"Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy","volume":"31","author":"Wada","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bbapap.2006.08.001_bib77","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s001250051587","article-title":"Renoprotective effects of a novel inhibitor of advanced glycation","volume":"44","author":"Forbes","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbapap.2006.08.001_bib78","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1046\/j.1432-1033.2003.03631.x","article-title":"The molecular chaperone alpha-crystallin incorporated into red cell ghosts protects membrane NaK-ATPase against glycation and oxidative stress","volume":"270","author":"Derham","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib79","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0891-5849(00)00410-X","article-title":"Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na+ and K+)- and Ca++-ATPase activities in high glucose-treated human erythrocytes","volume":"29","author":"Jain","year":"2000","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.bbapap.2006.08.001_bib80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.abb.2003.08.010","article-title":"Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation endproduct formation","volume":"419","author":"Miyata","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0925-4439(99)00102-7","article-title":"Fructose-mediated damage to lens \u03b1-crystallin: prevention by pyruvate","volume":"1500","author":"Zhao","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/10715769800300351","article-title":"Fructose-induced deactivation of glucose-6-phosphate dehydrogenase activity and its prevention by pyruvate: implications in cataract prevention","volume":"29","author":"Zhao","year":"1998","journal-title":"Free Radical Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib83","doi-asserted-by":"crossref","first-page":"48967","DOI":"10.1074\/jbc.M108196200","article-title":"Chelating activity of advanced glycation end product inhibitors","volume":"276","author":"Price","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0011-393X(00)89033-5","article-title":"Inhibitory effect of dilazep hydrochloride on the formation of advanced glycation end products","volume":"61","author":"Tanaka","year":"2000","journal-title":"Curr. Ther. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0925-4439(00)00087-9","article-title":"Inhibitors of advanced glycation end product-associated protein crosslinking","volume":"1535","author":"Lehman","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib86","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/diabetes.49.10.1627","article-title":"Identification, cloning and heterologous expression of a mammalian fructosamine-3-kinase","volume":"49","author":"Delpierre","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib87","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2337\/diabetes.50.9.2139","article-title":"Human fructosamine-3-kinase. Purification, sequencing, substrate specificity, and evidence of activity in vivo","volume":"50","author":"Szwergold","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib88","doi-asserted-by":"crossref","first-page":"27613","DOI":"10.1074\/jbc.M402091200","article-title":"Identification of fructosamine residues deglycated by fructosamine-3-kinase in human haemoglobin","volume":"279","author":"Delpierre","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib89","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1196\/annals.1333.095","article-title":"Some clues as to the regulation, expression, function and distribution of fructosamine-3-kinase and fructosamine-3-kinase-related protein","volume":"1043","author":"Connor","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib90","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.mehy.2004.09.022","article-title":"Alternative anti-glycation mechanisms: are spermine and fructosamine-3-kinase part of a damage control pathway","volume":"64","author":"Gugliucci","year":"2005","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbapap.2006.08.001_bib91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.abb.2003.08.011","article-title":"Enzymic deglycation of proteins","volume":"419","author":"Wu","year":"2005","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib92","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1262-3636(07)70244-6","article-title":"Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites","volume":"32","author":"Delpierre","year":"2006","journal-title":"Diabetes Med."},{"key":"10.1016\/j.bbapap.2006.08.001_bib93","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1042\/BJ20041976","article-title":"Plant ribulosamine\/erythrulosamine 3-kinase, a putative protein-repair enzyme","volume":"388","author":"Fortpied","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2006.08.001_bib94","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.mehy.2005.02.017","article-title":"Intrinsic toxicity of glucose, due to non-enzymic glycation, is controlled in vivo by deglycation systems including: FN3K-mediated deglycation of fructosamines and transglycation of aldosamines","volume":"65","author":"Szwergold","year":"2005","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbapap.2006.08.001_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbrc.2005.08.033","article-title":"Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases","volume":"336","author":"Szwergold","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbapap.2006.08.001_bib96","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.mehy.2005.10.029","article-title":"\u03b1-Thiolamines such as cysteine and cysteamine act as effective transglycating agents due to formation of irreversible thiazolidine derivatives","volume":"66","author":"Szwergold","year":"2006","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbapap.2006.08.001_bib97","series-title":"Cataract: Biochemistry, Epidemiology and Pharmacology","author":"Harding","year":"1991"},{"key":"10.1016\/j.bbapap.2006.08.001_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/382275a0","article-title":"An agent cleaving glucose-derived protein crosslinks in vitro and in vivo","volume":"382","author":"Vasan","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bbapap.2006.08.001_bib99","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0006-2952(98)00284-6","article-title":"Rapid hydrolysis and slow \u03b1,\u03b2-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links","volume":"57","author":"Thornalley","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib100","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1073\/pnas.95.8.4630","article-title":"Breakers of advanced glycation end products restore large artery properties in experimental diabetes","volume":"95","author":"Wolffenbuttel","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbapap.2006.08.001_bib101","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0003-9861(03)00015-8","article-title":"AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats","volume":"412","author":"Yang","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib102","doi-asserted-by":"crossref","first-page":"H2587","DOI":"10.1152\/ajpheart.00516.2003","article-title":"Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart","volume":"285","author":"Liu","year":"2003","journal-title":"Am. J. Physiol.: Heart Circ. Physiol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.abb.2003.08.016","article-title":"Therapeutic potential of breakers of advanced glycation end product-protein crosslinks","volume":"419","author":"Vasan","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbapap.2006.08.001_bib104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0141-8130(98)00027-0","article-title":"Protection of enzymes by \u03b1-crystallin acting as a molecular chaperone","volume":"22","author":"Hook","year":"1998","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1432-1033.1995.tb20684.x","article-title":"Molecular chaperones protect against glycation-induced inactivation of glucose 6-phosphate dehydrogenase","volume":"231","author":"Ganea","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib106","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1042\/bj20020924","article-title":"Enzyme activity after resealing within ghost erythrocyte cells, and protection by alpha-crystallin against fructose-induced inactivation","volume":"368","author":"Derham","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2006.08.001_bib107","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/0264-6021:3450467","article-title":"\u03b1-Crystallin assists the renaturation of glyceraldehyde-3-phosphate dehydrogenase","volume":"345","author":"Ganea","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbapap.2006.08.001_bib108","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1515\/BC.2005.032","article-title":"Trehalose and 6-aminohexanoic acid stabilize and renature glucose 6-phosphate dehydrogenase inactivated by glycation and by guanidinium hydrochloride","volume":"386","author":"Ganea","year":"2005","journal-title":"Biol. Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib109","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbadis.2006.02.004","article-title":"Comparison of protective effects of aspirin, d-penicillamine and vitamin E against high glucose-mediated toxicity in cultured endothelial cells","volume":"1762","author":"Zhang","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib110","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1021\/tx050074u","article-title":"Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins.","volume":"18","author":"Zeng","year":"2005","journal-title":"Chem. Res. Toxicol."},{"issue":"52","key":"10.1016\/j.bbapap.2006.08.001_bib111","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1021\/jf0307292","article-title":"Antioxidative and antiglycative effects of six organosulfur compounds in low-density lipoprotein and plasma","volume":"2","author":"Huang","year":"2004","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bbapap.2006.08.001_bib112","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000074065","article-title":"Hyper-vascular change and formation of advanced glycation endproducts in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite","volume":"23","author":"Nakayama","year":"2003","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib113","first-page":"189","article-title":"Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation","volume":"27","author":"Yamagishi","year":"2005","journal-title":"Int. J. Tissue React."},{"key":"10.1016\/j.bbapap.2006.08.001_bib114","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1196\/annals.1333.050","article-title":"Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia","volume":"1043","author":"Osawa","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nm834","article-title":"Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy","volume":"9","author":"Hammes","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbapap.2006.08.001_bib116","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.2337\/diabetes.52.8.2110","article-title":"Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine","volume":"52","author":"Babaei-Jadidi","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.bbapap.2006.08.001_bib117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00125-005-0103-5","article-title":"Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B\/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis","volume":"49","author":"Gadau","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.bbapap.2006.08.001_bib118","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2005.10.022","article-title":"Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha","volume":"13","author":"Wu","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbapap.2006.08.001_bib119","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s005920170010","article-title":"Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose","volume":"38","author":"Pomero","year":"2001","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.bbapap.2006.08.001_bib120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1196\/annals.1333.090","article-title":"High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats","volume":"1043","author":"Karachalias","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbapap.2006.08.001_bib121","first-page":"169","article-title":"Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation","volume":"30","author":"Yamagishi","year":"2004","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib122","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mvr.2005.10.002","article-title":"Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension","volume":"70","author":"Nakamura","year":"2005","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.bbapap.2006.08.001_bib123","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0014-5793(96)00134-2","article-title":"\u03b1-Crystallin acting as a molecular chaperone protects catalase against steroid-induced inactivation","volume":"382","author":"Hook","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbapap.2006.08.001_bib124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0925-4439(99)00087-3","article-title":"\u03b1-Crystallin protects glucose-6-phosphate dehydrogenase against inactivation by malondialdehyde","volume":"1500","author":"Ganea","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbapap.2006.08.001_bib125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0140-6736(92)91099-T","article-title":"Cyanate derived from urea in uraemia","volume":"339","author":"Harding","year":"1992","journal-title":"Lancet"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963906002603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570963906002603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:06:48Z","timestamp":1683547608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570963906002603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":125,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1570963906002603"],"URL":"https:\/\/doi.org\/10.1016\/j.bbapap.2006.08.001","relation":{},"ISSN":["1570-9639"],"issn-type":[{"value":"1570-9639","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}